New data from the phase 3 COMPETE trial point to the efficacy of the radiotherapy agent 177Lu-edotreotide for the treatment of patients with grade 1 or 2 somatostatin receptor (SSTR)–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 177Lu-edotreotide is an IV therapy composed of non-carrier–added lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a synthetic SSTR agonist. ...
GEP-NETs
Advertisement
A new retrospective study has examined the use of 68Ga-DOTATATE PET/CT in all stages of disease.
The combination of EVE/LAN can significantly prolong PFS in patients with well-differentiated grade 1/2 GEP-NETs.
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
The peripheral blood transcriptome of NET patients showed differential enrichment of 30 systemic cancer hallmarks.
A blood-based, non-invasive classifier can serve as an optional tool for conventional methods in the detection of NETs.
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.